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Abstract
Background: Recent clinical trials and observational studies have reported increased coronary events associated with non
steroidal anti-inflammatory drugs (NSAIDs). There appeared to be a disproportionate increase in non-fatal versus fatal
events, however, numbers of fatal events in individual studies were too small, and event rates too low, to be meaningful.
Objectives: We undertook a pooled analysis to investigate the effect of NSAIDs on myocardial infarction (MI) risk with the
specific aim to differentiate non-fatal from fatal events.
Methods: We searched Pubmed (January, 1990 to March, 2010) for observational studies and randomised controlled trials
that assessed the effect of NSAIDs (traditional or selective COX-2 inhibitors [coxibs]) on MI incidence separately for fatal and
non-fatal events. Summary estimates of relative risk (RR) for non-fatal and fatal MIs were calculated with a random effects
model.
Results: NSAID therapy carried a RR of 1.30 (95% CI, 1.20–1.41) for non-fatal MI with no effect on fatal MI (RR 1.02, 95% CI,
0.89–1.17) in six observational studies. Overall, the risk increase for non-fatal MI was 25% higher (95% CI, 11%–42%) than for
fatal MI. The two studies that included only individuals with prior cardiovascular disease presented risk estimates for non-
fatal MI on average 58% greater (95% CI, 26%–98%) than those for fatal MI. In nine randomised controlled trials, all
investigating coxibs, the pooled RR estimate for non-fatal MI was 1.61 (95% CI, 1.04–2.50) and 0.86 (95% CI 0.51–1.47) for
fatal MIs.
Conclusions: NSAID use increases the risk of non-fatal MI with no substantial effect on fatal events. Such differential effects,
with potentially distinct underlying pathology may provide insights into NSAID-induced coronary pathology. We studied
the association between the use of nonsteroidal anti-inflammatory drugs (NSAIDs) and the risk of myocardial infarction (MI),
separating non-fatal from fatal events, summarizing the evidence from both observational studies and randomised
controlled trials. An increased risk of non-fatal MI was clearly found in both types of studies while use of NSAID did not
confer an increased risk of fatal MI. Our findings provide support for the concept that thrombi generated under NSAID
treatment could be different from spontaneous thrombi.
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Introduction
Non-steroidal antiinflammatory drugs (NSAIDs) are cyclooxy-
genase inhibitors (COX-1 and 22) used commonly for the
treatment of acute and chronic pain. With recent randomised
studies demonstrating increased cardiovascular adverse events
associated with selective COX-2 inhibitors (coxibs)[1–4], there is
growing concern and evidence that NSAIDs predispose to
myocardial infarction (MI), particularly in those patients at highest
cardiovascular risk. The first study to show an increased risk of MI
with a coxib was the VIGOR trial [1], which was designed to
compare the gastrointestinal safety of rofecoxib and naproxen in
patients with rheumatoid arthritis. Although rofecoxib demon-
strated a lower risk of gastrointestinal events, there was a four- to
five-fold increased risk of MI among users of rofecoxib, but
restricted to non fatal events, with apparently no impact on
coronary heart disease (CHD) deaths. Due to the low event rate,
the clinical significance of this observation was uncertain. With
many more studies published since then, there is an opportunity to
assess more precisely the relationship between NSAIDs and MI
PLoS ONE | www.plosone.org 1 February 2011 | Volume 6 | Issue 2 | e16780according to its severity. No previous meta-analysis has addressed
separately the risk of non-fatal and fatal MI risk associated with
NSAID using both RCTs and observational studies.
We performed an analysis of all observational studies and
randomized controlled trials published between January 1990 and
March 2010 to summarize the impact of NSAIDs on fatal and
non-fatal MI in different population types.
Methods
We identified all observational studies and randomized
controlled trials exploring the association between NSAID use
and the occurrence of non-fatal MI and fatal-MI (including CHD
death), indexed in Pubmed between January 1990 and March
2010 without language restrictions. Additionally we also consid-
ered those studies included in previously published systematic
reviews. This was particularly useful in capturing data from
unpublished RCTs. Studies evaluating traditional NSAIDs
(tNSAIDs) and coxibs were considered when they provided either
separate estimates of risk for non-fatal MI and fatal-MI according
to NSAID use, or sufficient data to compute crude estimates.
Because the power of randomised controlled trials to study these
rare events is quite limited, we selected only those RCTs with a
total sample size greater than 1500, and an average accrued
follow-up longer than 6 months. Thus, even though individual
studies meeting these sample size and follow-up criteria would still
be largely underpowered, assuming an incidence rate of fatal cases
around 1.5 per 1000 person-years it would be expected that they
found at least one or more of these fatal cases. Additionally, these
inclusion criteria would improve homogeneity between studies
because only long-term follow-up studies were considered. Data
was extracted in duplicate and any discrepancies were resolved
through consensus. Extracted data included: type of design, study
period, sample size, mean follow-up (in prospective studies),
exposure definition, prior history of coronary heart disease
(observational studies), use of aspirin (randomized controlled
trials), fatal events, non fatal events, and specific estimates for the
risk of fatal and non-fatal events. When endpoint specific adjusted
estimates were not available and the number of fatal and non-fatal
events, as well as the number of exposed and unexposed person-
time, were available we estimated the crude incidence rate and
relative risk (RR). The detailed results of the study selection
process are shown in Figure 1.
In order to obtain weighted summary estimates we used random
effects models (Stata 10.0). Among observational studies, we
obtained separate pooled estimates according to whether prior
history of cardiovascular disease was an eligibility criterion to enter
the study. We also obtained separate pooled estimates for
randomised controlled trials according to the nature of the
comparison group (placebo/NSAID). Finally we explored hetero-
geneity of effects between non-fatal and fatal endpoints and
formally tested this hypothesis by fitting a meta-regression model
(stata metareg command). This model provides summary estimates
of the relative increase in non-fatal estimates compared to fatal
estimates in these studies associated with NSAIDs (odds ratio
[OR] and 95% confidence interval [CI]) and the corresponding p
values.
Results
Among observational studies we were able to obtain separate
estimates for fatal and non-fatal MI in six studies (Table 1) [5–10].
Studies not eligible were those that did not include fatal cases, did
not provide separate estimates, or considered as fatal cases all
deaths or all cardiovascular deaths. A total of 47 studies were
excluded for these reasons. Eligible studies include four cohort
studies [5,7,9,10] and two nested case-control studies [6,8]. The
total number of events in these studies ranged from 814 to 8852
Figure 1. Study selection process.
doi:10.1371/journal.pone.0016780.g001
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OR estimate for fatal and non-fatal MI risk among the 6 eligible
studies was 1.21 (95%CI, 1.07–1.37). Using a random effects
model, the summary OR estimate for the association between
current NSAID use and non-fatal MI was 1.30 (95% CI, 1.20–
1.41) compared with 1.02 (95% CI, 0.89–1.17) for fatal MI
(Figure 2). Therefore, no association was found between use of
NSAIDs and fatal MI. The estimates for non-fatal MI were on
average 25% larger than those for fatal MI (OR, 1.25; 95% CI,
1.11–1.42).
Two observational studies included only individuals with prior
CHD history [9] or prior cardiovascular events (defined as
ischaemic heart disease or ischaemic cerebrovascular event)[10].
In this particular subgroup of studies, estimates for non-fatal MI
were on average 58% greater than those for fatal MI (OR, 1.58;
95% CI, 1.26–1.98). The remaining four studies included either
individuals with no prior history of CHD or a percentage of
individuals with prior history below 25%. Among these studies the
estimates for non-fatal MIs compared to fatal MIs were of smaller
magnitude (OR, 1.19; 95% CI 1.08–1.31).
Nine randomised controlled trials were eligible for the analysis
[1,2,11–17]. A total of 127 trials were excluded due to small
sample size, short follow-up, or both. Sample sizes ranged from
1561 to 34,701 patients whereas average follow-up ranged from 6
months to about 3 years (Table 2). The number of events in
individual studies ranged from 4 to 210 for non-fatal MIs and 6 to
23 for fatal events. NSAID treatment arms always included coxibs
but the comparator group varied between placebo and tNSAIDs.
Overall, the summary estimates for the combined fatal and non-
fatal MI risk among the 5 placebo controlled trials and the 4 non
placebo-controlled trials were 1.76 (95%CI, 1.09–2.83) and 1.31
(95%CI, 0.78–2.18), respectively. The summary RR estimate for
non-fatal MI associated with current coxib use was 1.61 (95%CI,
1.04–2.50) using the random effects model while the correspond-
ing estimate for fatal MI was 0.86 (95%CI, 0.51–1.47) (Figure 3).
The estimate for non-fatal MI relative to fatal MI was of
Figure 2. Non steroidal anti-inflammatory drugs and risk for non-fatal and fatal myocardial infarctions in observational studies.
doi:10.1371/journal.pone.0016780.g002
Table 1. Risk of Non-fatal and Fatal cardiovascular events associated to non steroidal anti-inflammatory drugs in observational
studies.
STUDY Source
Age
(years) Study period Design
Exposure
definition* Prior CHD (%) Non-Fatal MI CHD death
nexposed (ntotal)n exposed (ntotal)
Ray
(5) Medicaid 50–84 1987–1998 Cohort tNSAID 0 days 22 NA (4224) NA (2138)
Garcia Rodriguez
(6) GPRD 50–84 1997–2000 Nested C-C tNSAIDs 0–30 days 17 366 (2886) 214 (1909)
Chan
(7) Nurses Health
Study
44–69{ 1990–2002 Cohort NSAIDs .22days/month 0 71 (814) 32 (277)
Garcia Rodriguez
(8) THIN 50–84 2000–2005 Nested C-C NSAIDs 0–6 days 17 901 (8852) 252 (3119)
Ray
(9) Medicaid +
Saskatchewan +
GPRD
40–89 1999–2004 Cohort{ NSAID 0 days 100 262 (2484) 96 (1116)
Garcia Rodriguez
(10) THIN 50–84 2000–2007 Cohort1 NSAIDs 0-6 days 100 89 (876) 23 (346)
*Number of days since last use, except in the study by Chan et al in which the current exposure was defined as more than 22 days of use in the last month.
{At baseline (Women only).
{Followed up after CHD hospitalization.
1Cohort of aspirin users.
C-C: Case-Control; CHD: Coronary Heart Disease; CI: Confidence Interval; GPRD: General Practitioner Research Database; MI:Myocardial Infarction; NA:Not Available;
NSAIDs: non steroidal anti-inflammatory drugs; RR: Relative Risk; THIN: The Health Network; tNSAIDs: traditional NSAIDs.
doi:10.1371/journal.pone.0016780.t001
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(Figure 4), although it included both placebo-controlled and
tNSAIDs-controlled trials. A secondary analysis restricted to the 5
placebo-controlled trials showed an increased risk for non-fatal
MIs (OR, 1.90; 95%CI, 1.05–3.41) but not for fatal events (OR,
1.37; 95%CI, 0.54–3.46). In this subgroup analysis, the OR of
non-fatal vs fatal MIs was 1.30 (95% CI, 0.41–4.12). The 4 trials
using tNSAIDs as comparators (naproxen, ibuprofen or diclofe-
nac) did not show a significant increased risk of either non-fatal MI
(OR, 1.48; 95%CI: 0.80–2.75) or of fatal MI (OR, 0.68; 95%CI,
0.36–1.31) associated with coxib treatment.
Incidence rates of non-fatal MI and CHD death were relatively
similar between observational studies and randomised controlled
trials. Except one outlier [9], observational studies reported
Figure 3. Non steroidal anti-inflammatory drugs and risk for non-fatal and fatal myocardial infarctions in randomised controlled
trials.
doi:10.1371/journal.pone.0016780.g003
Table 2. Risk of Non-fatal and Fatal cardiovascular events associated to non steroidal anti-inflammatory drugs in randomised
controlled trials.
STUDY Study Disease
Age
(yrs)
Mean
Follow-up
(yrs) Exposure
ASA
use
(%) Non-Fatal MI CHD death
Tx arm N
(%)
Ctrl arm N
(%)
Tx arm N
(%)
Ctrl arm N
(%)
APPROVe
(2) Removed colon
adenomas
.40 2.47 rofecoxib 25 mg (n=1287) vs.
placebo (n=1299)
17–16 19 (1.5%) 6 (0.5%) 2 (0.2%) 3 (0.2%)
APC
(14) Removed colon
adenomas
.30 3.01 celecoxib 200 mg bid (n=685) or
celecoxib 400 mg bid (n=671) vs.
placebo (n=679)
31 18 (1.3%) 3 (0.4%) 11 (0.8%) 1 (0.1%)
PreSAP
(14) Removed colon
adenomas
.30 2.5 celecoxib 400 mg (n=933) vs.
placebo (n=628)
17 9 (1.0%) 4 (0.6%) 4 (0.4%) 4 (0.6%)
VICTOR
(12) Stage II/III colorectal
carcinoma
- 0.79 rofecoxib 25 mg (n=1167) vs.
placebo (n=1160)
8.7–6.9 3 (0.3%) 1 (0.1%) 4 (0.3%) 2 (0.2%)
VIGOR
(1,11) Rheumatoid arthritis .40 0.57 rofecoxib 50 mg (n=4047) vs.
naproxen 500 mg bid (n=4029)
4{ 18 (0.4%) 4 (0.1%) 5 (0.1%) 4 (0.1%)
CLASS
(13) Rheumatoid arthritis/
Osteoarthitis
.18 0.57 celecoxib 400 mg bid (n=3987) vs.
diclofenac 75 mg bid (n=1996) or
ibuprofen 800 mg tid (n=1985)
22 12 (0.3%) 11 (0.3%) 9 (0.2%) 8 (0.2%)
TARGET
(16) Osteoarthitis .50 0.74 lumiracoxib 400 mg (n=9156) vs.
naproxen 500 mg bid (n=4754) or
ibuprofen 800 mg tid (n=4415)
24 18 (0.2%) 9 (0.1%) 2 (0.02%) 3 (0.03%)
ADAPT
(15) Family history of
Alzheimer’s disease
.70 1.84 celecoxib 200 mg bid (n=726) vs.
placebo (n=1083)
56 8 (1.1%) 13 (1.2%) 4 (0.6%) 3 (0.3%)
EDGE/MEDAL
(17) Rheumatoid arthritis/
Osteoarthitis
.50 1.46 etoricoxib 60–90 mg (n=17412) vs.
diclofenac 150 mg (n=17289)
34 105 (0.62%) 105 (0.64%) 6 (0.04%) 17 (0.10%)
*Crude Rate Ratios and exact 95% CI are calculated for each study dividing the rate of events in treatment arms over the rate of events in control arms. Crude rates are
estimated from the reported number of events and the patient-years of exposure in each arm.
{Prior History of Coronary Heart Disease.
ASA: Acetyl Salicylic Acid (aka aspirin); CHD: Coronary Heart Disease; CI: Confidence Interval; MI:Myocardial Infarction; RR: Relative Risk; Tx:Treatment; Crtl: Control.
doi:10.1371/journal.pone.0016780.t002
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fatal MI and between 0.3 and 4 for CHD deaths. The
corresponding estimates of incidence in randomised controlled
trials were between 2 and 5 per 1,000 person-years and 0.4 and 3,
respectively.
Discussion
This pooled analysis reviewing multiple and diverse studies
supports the conclusion that NSAID treatment, including both
tNSAIDs and coxibs, predisposes to non-fatal myocardial
infarction, but only a marginal effect on coronary mortality risk
was found. This is important because the elderly population,
which has an increased cardiovascular risk, is the major consumer
of NSAIDs, so the consistency of our finding of an increased risk of
non-fatal MI is of great concern. However, the finding of a lack of
coronary-related mortality increase in NSAID users may be
considered somewhat reassuring for those who need to be treated
with NSAIDs. The hazard of non-fatal cardiovascular events
should be taken into consideration when prescribing these drugs in
high-risk patients [18].
Based on current knowledge, the underlying pathophysiology of
NSAID-associated coronary risk can only be speculated. As
patient characteristics are well balanced between patients assigned
to the NSAID or control (placebo or active) arms in randomised
trials, more advanced coronary disease or other comorbidities (e.g.
heart failure, diabetes) are unlikely to be the major explanation for
the selective increase in nonfatal cardiovascular events. The
differential effects of COX-1 and COX-2 inhibition, regulating
thrombus formation [4] is the most plausible mechanism. Selective
COX-1 inhibition such as the one produced by low-dose aspirin
has been shown to have an antithrombotic effect mediated by a
relatively specific, potent, and irreversible inhibition of platelet
COX-1, which reduces thromboxane A2 biosynthesis, a powerful
trigger of platelet aggregation [19]. Randomised controlled trials
with low dose aspirin have consistently shown a clear reduction in
risk of non fatal MI and to a lesser extent fatal MI in high risk
patients [21–25]. In contrast COX-2 inhibition with the resulting
suppression of prostacyclin and other hemostatic mediators
increase the risk of coronary thrombosis [20]. Thus, an incomplete
antithrombotic effect of COX-1 inhibition may counteract the
prothrombotic effects of COX-2 inhibition afforded by NSAIDs
leading to non-fatal rather than fatal events. A recent study
showed that NSAIDs only increase the risk of non-ST-segment
elevation acute coronary syndromes but not of ST-segment
elevation MI [26]. As the former are related to incomplete
occlusion of major coronary arteries or occlusion of smaller
coronary arteries [27], it was hypothesized that NSAID-related
thrombosis might be less severe than spontaneous coronary
thrombosis. Whether coronary thrombi generated under NSAID
treatment are different in stability or location from spontaneous
thrombi remains to be explored. To directly address the hypothesis
that the COX-1 inhibition component of NSAIDs reduces
damage caused by MI (shifts the balance towards non fatal MI),
the case-fatality effect of NSAIDs individually according to their
degree of COX-1 and COX-2 inhibition needs to be assessed.
Unfortunately, the current study numbers at the individual level
are insufficient to reach any meaningful conclusion.
Only a small number of studies originally reported fatal and
non-fatal events separately and met our eligibility criteria. These
may not be representative of the majority of published studies in
the field. Yet, when we analyzed the combined estimate (fatal and
non-fatal MI) in our subset of studies, the results are similar to
those reported in previous meta-analyses of observational studies
[28,29] and RCTs [30]. Our review of studies addressing the risk
of non-fatal MI and CHD deaths include observational studies,
which are susceptible to bias and confounding but based upon the
consistency of results across the observational studies and the
RCTs, which have well balanced baseline characteristics, it is
unlikely that our finding of can be entirely explained by bias. We
found some evidence of heterogeneity in our analyses that reached
statistical significance for the pooled estimate of fatal events among
observational studies (Figure 2). In this context, the use of random
effects models is favoured over fixed effects models. Additionally
Figure 4. Relative risk estimates for non-fatal compared to fatal myocardial infarction risk associated with use of non steroidal anti-
inflammatory drugs by type of study.
doi:10.1371/journal.pone.0016780.g004
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metaregression model and exploring the effect of different study
characteristics (such as the inclusion criteria in observational
studies or the use of placebo in RCTs) on the pooled estimate.
Overall, there were insufficient data to assess the risk of non-fatal
and fatal MI among individual traditional NSAIDs, or whether
there is any difference between traditional NSAIDs and coxibs.
This should be the ultimate goal as it has been previously shown
that individual NSAIDs at commonly used doses, present
variability in their magnitude of risk of ischemic coronary disease
[4,8]. Also, despite our criteria of minimum total sample size and
follow-up requirements the power of RCTs to study these rare
events is quite limited due to the paucity of events. The inclusion
of smaller RCTs with few or no events would provide very little
additional information to our risk estimates.
NSAIDs increase the risk of non-fatal MI but do not increase
coronary heart disease mortality. Due to the widespread use of
NSAIDs in the population, particularly amongst the elderly,
further research is urgently needed to unravel the specific
mechanisms involved in NSAID-associated coronary thrombosis
(including genetic and epigenetic markers) and the identification of
patients at highest risk of such complication. Additionally, studies
are warranted to reduce the coronary risk associated with NSAID
use.
Author Contributions
Conceived and designed the experiments: LAGR AG-P. Performed the
experiments: LAGR AG-P. Analyzed the data: LAGR AG-P JH. Wrote
the paper: LAGR AG-P JH HB.
References
1. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, et al. (2000)
Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in
patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 343:
1520–1528.
2. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, et al. (2005)
Cardiovascular events associated with rofecoxib in a colorectal adenoma
chemoprevention trial. N Engl J Med 352: 1092–1102.
3. Solomon SD, Wittes J, Finn PV, Fowler R, Viner J, et al. (2008) Cardiovascular
risk of celecoxib in 6 randomized placebo- controlled trials: the cross trial safety
analysis. Circulation 117: 2104–13.
4. Grosser T, Fries S, FitzGerald GA (2006) Biological basis for the cardiovascular
consequences of COX-2 inhibition: therapeutic challenges and opportunities.
Invest J Clin 116: 4–15.
5. Ray WA, Stein CM, Hall K, Daugherty JR, Griffin MR (2002) Non-steroidal
anti-inflammatory drugs and risk of serious coronary heart disease: an
observational cohort study. Lancet 359: 118–123.
6. Garcı ´a Rodrı ´guez LA, Varas-Lorenzo C, Maguire A, Gonza ´lez-Pe ´rez A (2004)
Nonsteroidal antiinflammatory drugs and the risk of myocardial infarction in the
general population. Circulation 109: 3000–3006.
7. Chan AT, Manson JE, Albert CM, Chae CU, Rexrode KM, et al. (2006)
Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardio-
vascular events. Circulation 113: 1578–1587.
8. Garcı ´a Rodrı ´guez LA, Tacconelli S, Patrignani P (2008) Role of dose potency in
the prediction of risk of myocardial infarction associated with nonsteroidal anti-
inflammatory drugs in the general population. J Am Coll Cardiol 52:
1628–1636.
9. Ray WA, Varas-Lorenzo C, Chung CP, Castellsague J, Murray KT, et al. (2009)
Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after
hospitalization for serious coronary heart disease. Circ Cardiovasc Qual
Outcomes 2: 155–163.
10. Garcı ´a Rodrı ´guez LA, Cea Soriano L, Martı ´n-Merino E, Johansson S (2009)
Discontinuation of Low-Dose cetylsalicylic Acid Treatment for Secondary
Prevention of Cardiovascular Outcomes is Associated With an Increased Risk of
Myocardial Infarction. Circulation 120: S405.
11. Curfman GD, Morrissey S, Drazen JM (2006) Expression of concern reaffirmed.
N Engl J Med 354: 1193.
12. Kerr DJ, Dunn JA, Langman MJ, Smith JL, Midgley RS, et al. (2007) Rofecoxib
and cardiovascular adverse events in adjuvant treatment of colorectal cancer.
N Engl J Med 357: 360–369.
13. White WB, Faich G, Whelton A, Maurath C, Ridge NJ, et al. (2002)
Comparison of thromboembolic events in patients treated with celecoxib, a
cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac. Am J Cardiol
89: 425–430.
14. Solomon SD, Pfeffer MA, McMurray JJ, Fowler R, Finn P, et al. (2006) Effect of
celecoxib on cardiovascular events and blood pressure in two trials for the
prevention of colorectal adenomas. Circulation 114: 1028–1035.
15. ADAPT Research Group (2006) Cardiovascular and Cerebrovascular Events in
the Randomized, Controlled Alzheimer’s Disease Anti-Inflammatory Prevention
Trial (ADAPT). PLOS Clin Trial 1: e33.
16. Farkouh ME, Kirshner H, Harrington RA, Ruland S, Verheugt FW, et al.
(2004) Comparison of lumiracoxib with naproxen and ibuprofen in the
Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET),
cardiovascular outcomes: randomised controlled trial. Lancet 364: 675–684.
17. Cannon CP, Curtis SP, FitzGerald GA, Krum H, Kaur A, et al. (2006)
Cardiovascular outcomes with etoricoxib and diclofenac in patients with
osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and
Diclofenac Arthritis Long-term (MEDAL) programme: a randomised compar-
ison. Lancet 368: 1771–1781.
18. Bennett JS, Daugherty A, Herrington D, Greenland P, Roberts H, et al. (2005)
The use of nonsteroidal anti-Inflammatory drugs (NSAIDs): a science advisory
from the American Heart Association. Circulation 11: 1713–6.
19. Patrono C, Ciabattoni G, Patrignani P, Pugliese F, Filabozzi P, et al. (1985)
Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation 72:
1177–84.
20. FitzGerald GA, Patrono C (2001) The coxibs, selective inhibitors of
cyclooxygenase-2. N Engl J Med 345: 433–42.
21. Patrono C, Coller B, FitzGerald GA, Hirsh J, Roth G (2004) Platelet-active
drugs: the relationships among dose, effectiveness, and side effects: the Seventh
ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126(3
Suppl): 234S–264S.
22. Antiplatelet Trialists’ Collaboration (1994) Collaborative overview of rando-
mised trials of antiplatelet therapy I: prevention of death, myocardial infarction,
and stroke by prolonged antiplatelet therapy in various categories of patients.
BMJ 308: 81–106.
23. Antiplatelet Trialists’ Collaboration (2002) Prevention of death, myocardial
infarction and stroke by antiplatelet therapy in high-risk patients. BMJ 324:
71–86.
24. Patrono C, Garcı ´a Rodrı ´guez LA, Landolfi R, Baigent C (2005) Low-dose
aspirin for the prevention of atherothrombosis. N Engl J Med 353: 2373–83.
25. Antithrombotic Trialists’ (ATT) Collaboration, Baigent C, Blackwell L,
Collins R, Emberson J, et al. (2009) Aspirin in the primary and secondary
prevention of vascular disease: collaborative meta-analysis of individual
participant data from randomised trials. Lancet 373: 1849–60.
26. Bueno H, Bardajı ´ A, Patrignani P, Martı ´n-Merino E, Garcı ´a-Rodrı ´guez LA,
et al. (2010) Use of non-steroidal antiinflammatory drugs and type-specific risk of
acute coronary syndrome. Am J Cardiol 105: 1102–6.
27. Cannon C P, Braunwald E (2008) – Unstable Angina and Non-ST Elevation
Myocardial Infarction. In Libby: Braunwald’s Heart Disease: A textbook of
Cardiovascular Medicine, 8
th Ed Libby P, Bonow RO, Mann DL, Zipes DP,
eds. Philadelphia: Saunders Elsevier. pp 1319–1320.
28. Herna ´ndez-Dı ´az S, Varas-Lorenzo C, Garcı ´a Rodrı ´guez LA (2006) Non-
steroidal antiinflammatory drugs and the risk of acute myocardial infarction.
Basic Clin Pharmacol Toxicol 98: 266–74.
29. McGettigan P, Henry D (2006) Cardiovascular risk and inhibition of
cyclooxygenase: a systematic review of the observational studies of selective
and nonselective inhibitors of cyclooxygenase 2. JAMA 296: 1633–44.
30. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, et al. (2006) Do
selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflam-
matory drugs increase the risk of atherothrombosis? Meta-analysis of
randomised trials. BMJ 332: 1302–8.
NSAIDs, Non-Fatal and Fatal MI Risk
PLoS ONE | www.plosone.org 6 February 2011 | Volume 6 | Issue 2 | e16780